TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an announcement.
Recordati reported strong financial results for the first nine months of 2025, with a 12.2% increase in consolidated net revenues and an 11.8% rise in EBITDA. The company doubled its peak year sales estimates for Isturisa® to over €1.2 billion, driven by its expansion in the Cushing’s syndrome market. Despite a challenging macroeconomic environment, Recordati remains confident in achieving its financial year targets, supported by robust growth in both its Specialty & Primary Care and Rare Diseases sectors.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR55.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is a pharmaceutical company based in Milan, Italy, focusing on the Specialty & Primary Care and Rare Diseases segments. The company is known for its therapeutic products in urology, cardiovascular, gastrointestinal, endocrinology, onco-hematology, and metabolic franchises, with a significant market presence in Europe and the United States.
Average Trading Volume: 231,191
Technical Sentiment Signal: Hold
Current Market Cap: €10.26B
See more data about REC stock on TipRanks’ Stock Analysis page.